Literature DB >> 22954966

Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers.

Zufan Debebe1, Sergei Nekhai, Meseret Ashenafi, David B Lovejoy, Danuta S Kalinowski, Victor R Gordeuk, W Malcolm Byrnes, Des R Richardson, Pradeep K Karla.   

Abstract

In the current study, we developed a HPLC method to quantitatively measure the permeability of the BpT-based chelators, 2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (Bp4eT) and 2-benzoylpyridine 4-allyl-3-thiosemicarbazone (Bp4aT), across human colorectal adenocarcinoma (Caco-2) monolayers as a model of gut absorption. In aqueous solution, Bp4eT and Bp4aT formed inter-convertible Z and E isomers that were resolved by HPLC. Peak area was linear with respect to chelator concentration. Acceptable within-day and between-day precision (<22%) and accuracy (85-115% of true values) were obtained over a range of 1.0-100μM for Bp4eT and 1.5-300μM for Bp4aT. Limits of detection were 0.3μM and 1μM for Bp4eT and Bp4aT, respectively, while corresponding limits of quantification were 1μM and 5μM. Both chelators showed significant ability to chelate iron in THP-1 cells using a calcein-based assay and no apparent cytotoxicity was observed within 24h. Ratios of the apical to basolateral and basolateral to apical transport for Bp4eT were 1.10 and 0.89 at 100μM and 300μM respectively, indicating equal bi-directional movement of the compounds. Similarly, ratios were 0.77 and 0.92 for Bp4aT, respectively. This study demonstrates that Bp4eT and Bp4aT can be efficiently transported through Caco-2 cells and can potentially be formulated for oral delivery.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22954966      PMCID: PMC3457786          DOI: 10.1016/j.jchromb.2012.08.011

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  33 in total

1.  Iron status and the severity of HIV infection in pregnant women.

Authors:  G A Weinberg; H Friis; J R Boelaert; E D Weinberg
Journal:  Clin Infect Dis       Date:  2001-12-15       Impact factor: 9.079

2.  Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.

Authors:  Renzo Galanello; Antonio Piga; Daniele Alberti; Marie-Claude Rouan; Hilde Bigler; Romain Séchaud
Journal:  J Clin Pharmacol       Date:  2003-06       Impact factor: 3.126

Review 3.  Anti-HIV effect of iron chelators: different mechanisms involved.

Authors:  B S van Asbeck; N A Georgiou; T van der Bruggen; M Oudshoorn; H S Nottet; J J Marx
Journal:  J Clin Virol       Date:  2001-02       Impact factor: 3.168

4.  Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.

Authors:  N A Georgiou; T van der Bruggen; M Oudshoorn; H S Nottet; J J Marx; B S van Asbeck
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

5.  Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9.

Authors:  Zufan Debebe; Tatyana Ammosova; Denitra Breuer; David B Lovejoy; Danuta S Kalinowski; Krishna Kumar; Marina Jerebtsova; Patricio Ray; Fatah Kashanchi; Victor R Gordeuk; Des R Richardson; Sergei Nekhai
Journal:  Mol Pharmacol       Date:  2010-10-18       Impact factor: 4.436

6.  Phorbol myristate acetate-differentiated THP-1 cells display increased levels of MHC class I and class II mRNA and interferon-gamma-inducible tumoricidal activity.

Authors:  A Asseffa; L A Dickson; S Mohla; T A Bremner
Journal:  Oncol Res       Date:  1993       Impact factor: 5.574

7.  Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.

Authors:  Fuxing Tang; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

8.  Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.

Authors:  Shufeng Zhou; Xia Feng; Philip Kestell; Bruce C Baguley; James W Paxton
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-09-25       Impact factor: 3.205

9.  Treatment of iron overload in adults with continuous parenteral desferrioxamine.

Authors:  B Cooper; H F Bunn; R D Propper; D G Nathan; D S Rosenthal; W C Moloney
Journal:  Am J Med       Date:  1977-12       Impact factor: 4.965

10.  The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers.

Authors:  K O Hamilton; L Stallibrass; I Hassan; Y Jin; C Halleux; M Mackay
Journal:  Br J Haematol       Date:  1994-04       Impact factor: 6.998

View more
  4 in total

1.  Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase IκB-α expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription.

Authors:  Namita Kumari; Sergey Iordanskiy; Dmytro Kovalskyy; Denitra Breuer; Xiaomei Niu; Xionghao Lin; Min Xu; Konstantin Gavrilenko; Fatah Kashanchi; Subhash Dhawan; Sergei Nekhai
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate--ZMC1.

Authors:  Hongxia Lin; Xin Yu; Oliver S Eng; Brian Buckley; Ah-Ng Tony Kong; Joseph R Bertino; Darren R Carpizo; Murugesan K Gounder
Journal:  Biomed Chromatogr       Date:  2015-05-05       Impact factor: 1.902

3.  In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.

Authors:  Eliška Potůčková; Jaroslav Roh; Miloslav Macháček; Sumit Sahni; Ján Stariat; Vít Šesták; Hana Jansová; Pavlína Hašková; Anna Jirkovská; Kateřina Vávrová; Petra Kovaříková; Danuta S Kalinowski; Des R Richardson; Tomáš Šimůnek
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

4.  Synthesis and Antibacterial Activity of Novel Hydroxy Semicarbazone Derivatives.

Authors:  Elham Hariri; Arash Mahboubi; Mohammad Fathi; Parisa Rahmani; Kamaleddin Haj Mohammad Ebrahim Tehrani; Mohammad Babaeian; Vida Mashayekhi; Farzad Kobarfard
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.